[6-(二甲氨基)-4-甲基-3-吡啶基]-硼酸 | 535934-70-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: [6-(二甲氨基)-4-甲基-3-吡啶基]-硼酸
• 中文别名: 6-(二甲基氨基)-3-吡啶硼酸盐酸盐
• 英文名称: [6-(dimethylamino)-4-mefhylpyridin-3-yl]boronic acid
• 英文别名: (6-(dimethylamino)-4-methylpyridin-3-yl)boronic acid；2-dimethylamino-4-methyl-5-pyridyl boronic acid；[6-(dimethylamino)-4-methylpyridin-3-yl]boronic acid
• CAS: 535934-70-4
• 化学式: C₈H₁₃BN₂O₂
• 分子量: 180.014
• InChiKey: CVPDQSRAEJAOCP-UHFFFAOYSA-N

物化性质

• 沸点：
  381.4±52.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.86
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  56.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [6-(二甲氨基)-4-甲基-3-吡啶基]-硼酸 、 3-bromo-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-ol 在 tris-(dibenzylideneacetone)dipalladium(0) 、 三叔丁基膦 、 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 以77%的产率得到3-(4-methyl-6-dimethylaminopyridin-3-yl)-2,5-dimethyl-7-hydroxypyrazolo[1,5-a]pyrimidine
  参考文献：
  名称：

  [EN] CRF RECEPTOR ANTAGONISTS AND METHODS OF USE
  [FR] ANTAGONISTES DU RÉCEPTEUR CRF ET PROCÉDÉS D'UTILISATION

  摘要：

  本文提供了一些拮抗促肾上腺皮质激素释放因子（CRF）受体的化合物，特别是CRF受体1（CRF1），以及相关的制剂、组合物和治疗疾病和/或疾病的方法，这些疾病和/或疾病可以从中受益，如先天性肾上腺皮质增生症（CAH）。

  公开号：

  WO2021113263A1
• 作为产物：
  描述：

  在 水 、 溶剂黄146 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 生成 [6-(二甲氨基)-4-甲基-3-吡啶基]-硼酸
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of 8-(Pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: Potent, Orally Bioavailable Corticotropin Releasing Factor Receptor-1 (CRF₁) Antagonists

  摘要：

  This report describes the syntheses and structure-activity relationships of 8-(substituted pyridyl)pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF1) receptor antagonists. These CRF1 receptor antagonists may be potential anxiolytic or antidepressant drugs. This research resulted in the discovery of compound 13-15, which is a potent, selective CRF1 antagonist (hCRF(1) IC50 = 6.1 +/- 0.6 nM) with weak affinity for the CRF-binding protein and biogenic amine receptors. This compound also has a good pharmacokinetic profile in dogs. Analogue 13-15 is orally effective in two rat models of anxiety: the defensive withdrawal (situational anxiety) model and the elevated plus maze test. Analogue 13-15 has been advanced to clinical trials.

  DOI：

  10.1021/jm900025h

文献信息

• [EN] QUINOLINE EZH2 INHIBITORS<br/>[FR] INHIBITEURS QUINOLÉINE D'EZH2
  申请人：BAYER PHARMA AG

  公开号：WO2017025493A1

  公开（公告）日：2017-02-16

  The present invention relates to quinolines of general formula (I) to methods for their preparation, to intermediates for their preparation, to pharmaceutical compositions comprising at least one of those compounds, and to the use thereof.

  本发明涉及通式(I)的喹啉化合物，以及其制备方法、制备中间体、包含至少一种这些化合物的药物组合物，以及它们的用途。
• [EN] COMPOUNDS AS CRF1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSES UTILISES COMME ANTAGONISTES DU RECEPTEUR DE TYPE 1 DE LA CORTICOLIBERINE (CRF)
  申请人：UPJOHN CO

  公开号：WO2004099201A1

  公开（公告）日：2004-11-18

  The present invention relates to compounds of Formula I,or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compounds of the inventions are CRF, receptor antagonists. Compounds of the invention are useful for treating, in a warm-blooded animal, particularly a mammal, and more particularly a human, various disorders that are associated with CRF or CRF, receptors, or disorders the treatment of which can be effected or facilitated by antagonizing CRF, receptors.

  本发明涉及公式I的化合物，或其立体异构体，其药学上可接受的盐，或其前体。本发明的化合物是CRF受体拮抗剂。本发明的化合物可用于治疗温血动物，尤其是哺乳动物，更特别是人类，与CRF或CRF受体相关的各种疾病，或者通过拮抗CRF受体来治疗或促进治疗的疾病。
• Substituted aryl 1, 4-pyrazine derivatives
  申请人：Verhoest R. Patrick

  公开号：US20050049257A1

  公开（公告）日：2005-03-03

  Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.

  本发明揭示了替代芳基1,4-吡嗪衍生物及其在治疗焦虑症、抑郁症和与压力相关的疾病中的应用。
• Substituted aryl 1,4-pyrazine derivatives
  申请人：——

  公开号：US20030144297A1

  公开（公告）日：2003-07-31

  Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.

  本发明揭示了用于治疗焦虑症、抑郁症和与压力相关的疾病的取代芳基1,4-吡嗪衍生物及其使用。
• Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: Optimization studies and demonstration of in vivo efficacy
  作者：Mark S. Plummer、Joseph Cornicelli、Howard Roark、Donald J. Skalitzky、Charles J. Stankovic、Susan Bove、Jayvardhan Pandit、Annise Goodman、James Hicks、Aurash Shahripour、David Beidler、Xiao Kang Lu、Brian Sanchez、Christopher Whitehead、Ron Sarver、Timothy Braden、Richard Gowan、Xi Qiang Shen、Katherine Welch、Adam Ogden、Nalini Sadagopan、Heidi Baum、Howard Miller、Craig Banotai、Cindy Spessard、Sandra Lightle

  DOI：10.1016/j.bmcl.2013.03.082

  日期：2013.6

  Selective phosphodiesterase 2 (PDE2) inhibitors are shown to have efficacy in a rat model of osteoarthritis (OA) pain. We identified potent, selective PDE2 inhibitors by optimizing residual PDE2 activity in a series of phosphodiesterase 4 (PDE4) inhibitors, while minimizing PDE4 inhibitory activity. These newly designed PDE2 inhibitors bind to the PDE2 enzyme in a cGMP-like binding mode orthogonal to the cAMP-like binding mode found in PDE4. Extensive structure activity relationship studies ultimately led to identification of pyrazolodiazepinone, 22, which was >1000-fold selective for PDE2 over recombinant, full length PDEs 1B, 3A, 3B, 4A, 4B, 4C, 7A, 7B, 8A, 8B, 9, 10 and 11. Compound 22 also retained excellent PDE2 selectivity (241-fold to 419-fold) over the remaining recombinant, full length PDEs, 1A, 4D, 5, and 6. Compound 22 exhibited good pharmacokinetic properties and excellent oral bioavailability (F = 78%, rat). In an in vivo rat model of OA pain, compound 22 had significant analgesic activity 1 and 3 h after a single, 10 mg/kg, subcutaneous dose. (C) 2013 Elsevier Ltd. All rights reserved.